Literature DB >> 24636833

The pros and cons of lamivudine vs. entecavir in decompensated or severe acute exacerbation of chronic hepatitis B.

Daniel Shouval1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24636833     DOI： 10.1016/j.jhep.2014.03.004

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  4 in total

1.  Potent antiviral therapy improves survival in acute on chronic liver failure due to hepatitis B virus reactivation.

Authors:  Cyriac Abby Philips; Shiv Kumar Sarin
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

2.  Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation.

Authors:  Chao-Hung Hung; Tsung-Hui Hu; Sheng-Nan Lu; Chuan-Mo Lee; Chih-Hung Chen; Kwong-Ming Kee; Jing-Houng Wang; Ming-Chao Tsai; Yuan-Hung Kuo; Kuo-Chin Chang; Yi-Chun Chiu; Chien-Hung Chen
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

3.  Plasma-Derived Exosomal SncRNA as a Promising Diagnostic Biomarker for Early Detection of HBV-Related Acute-on-Chronic Liver Failure.

Authors:  Wenli Xu; Mingxue Yu; Yuankai Wu; Yusheng Jie; Xiangyong Li; Xinxin Zeng; Fangji Yang; Yutian Chong
Journal:  Front Cell Infect Microbiol       Date:  2022-07-07       Impact factor: 6.073

Review 4.  Chronic Hepatitis B with Spontaneous Severe Acute Exacerbation.

Authors:  Wei-Lun Tsai; Wei-Chi Sun; Jin-Shiung Cheng
Journal:  Int J Mol Sci       Date:  2015-11-26       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.